An observational study in Ulcerative Colitis (Disorder), sponsored by Gerhard Rogler. Not yet recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Gerhard Rogler · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Colitis, Ulcerative with a site in Switzerland — 11 open to participants now, 22 under way, 12 of them phase 3. Colitis, Ulcerative · Switzerland.
Among the 62 studies in Colitis, Ulcerative with a site in Switzerland, this one is the 6th largest by planned enrollment of the 12 observational ones that give a count, is one of 4 that started in 2026, is one of 12 observational ones, reaches primary completion later than 13 of the 21 other live ones, and was the 62nd registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →11 of the 62 studies in Colitis, Ulcerative with a site in Switzerland are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in Switzerland, United States, Argentina and 30 more countries
Ages 18+
Janssen-Cilag A.G., Switzerland · Sites in Switzerland
Ages 18+
Sanofi · Sites in Switzerland, United States, Argentina and 28 more countries
Ages 16–80
Takeda · Sites in Switzerland, United States, Belgium and 11 more countries
Ages 2–17
Sanofi · Sites in Switzerland, United States, Argentina and 22 more countries
Ages 16–80
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 15 · Phase 3 34 · Phase 4 1
First in 2001; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 280 is above the median of 198 across 551 observational studies indexed under Colitis, Ulcerative.
Median enrollment 540 across the 50 interventional studies, 260 across the 12 observational. Of the 35 that completed or were terminated, 25 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 62 have an industry lead sponsor. The 10 most frequent:
Gerhard Rogler is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Gerhard Rogler has 1 study filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
6 of the studies in Colitis, Ulcerative with a site in Switzerland that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
| NCT06029972Gilead SciencesStudy of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01 |
| NCT07012395Spyre Therapeutics, Inc.A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis | 2027-06 |
| NCT05496348AbbVieStudy of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis | 2027-08 |
Add all 6 to your calendar (.ics) → With an account.
Among the 62 studies in Colitis, Ulcerative with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, single-arm, observational, multicentre study conducted at four centres in Switzerland. A total of 280 adult patients with moderately active UC (Mayo score 6-12) initiating or receiving standard-of-care treatment will be enrolled. Patients will undergo standard disease monitoring according to STRIDE II recommendations, including clinical assessment, endoscopy, histology and faecal calprotectin. In addition, anorectal manometry and rectal barostat measurements will be performed at baseline and after 12 weeks of treatment. The primary endpoint is the presence of visceral hypersensitivity, defined as a discomfort/pain threshold below 90% of maximal rectal capacity during rectal distension, in patients achieving endoscopic mucosal healing (Mayo endoscopic score 0) compared with those without mucosal healing. Secondary endpoints include anorectal motor function, histological remission (Geboes score), predictors of mucosal healing and urgency resolution, and correlations between rectal hypersensitivity and faecal calprotectin.
Adult patients with moderately active ulcerative colitis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult Patients with ulcerative colitis and urgency (Mayo Score between 6-12, inclusive, with a score of at least 2 on either stool frequency or rectal bleeding, or an endoscopic sub-score of at least 2 upon endoscopic examination)
Other: there will be no study interventional therapy as this is a single arm observational study
there will be no study interventional therapy as this is a single arm observational study
presence of visceral hypersensitivity
The primary objective of the study is to test the presence of urgency according to objective parameters (anorectal motor function using anorectal manometry and validated clinical outcome parameters) in ulcerative colitis patients who achieve mucosal healing (as defined by endoscopy) after 12 weeks upon standard treatment as compared to patients who do not achieve mucosal healing.
Time frame: 12 weeks
Urgency according to histological mucosal healing
Urgency according to histological mucosal healing: Comparison of urgency between patients with and without histological mucosal healing after 12 weeks of standard treatment. (Units on a Scale)
Time frame: 12 weeks
Predictors of endoscopic mucosal healing:
Evaluation of age (years) as predictor of mucosal healing (yes/no)
Time frame: 12 weeks
Predictors of endoscopic mucosal healing
Evaluation of age at onset (years) as predictor of mucosal healing (yes/no)
Time frame: 12 weeks
Predictors of endoscopic mucosal healing
Disease duration (years), as predictor of mucosal healing (yes/no)
Time frame: 12 weeks
Predictors of endoscopic mucosal healing
Disease extent (procitis, left sided colitis, extensive colitis) as predictor of mucosal healing (yes/no)
Time frame: 12 weeks
Predictors of endoscopic mucosal healing
Number of previous treatments (number) as predictor of mucosal healing (yes/no)
Time frame: 12 weeks
Urgency resolution (Urgency Numeric Rating Scale)
Assessment of urgency resolution using the Urgency Numeric Rating Scale (1-10)
Time frame: 12 wekks
Urgency resolution (Bowel Urgency Frequency)
Assessment of urgency resolution using Bowel Urgency Frequency or BUF ( Units on a Scale)
Time frame: 12 weeks
Urgency resolution (Sensory Detection Threshold)
Assessment of urgency resolution using Sensory Detection Threshold or SDT ( Units on a Scale)
Time frame: 12 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.
Of 188 non-industry observational studies under Colitis, Ulcerative, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 119. This study's planned 13 months is below that.
Counting every sponsor, half of 271 studies reached it within 47 months; a quarter within 29 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gerhard Rogler